CD79A and nasopharyngeal carcinoma: Although EBV DNA and antibodies against EBV antigens (e.g. VCA-IgA) are clinically used for NPC for many years, they may be of limited use as general screening test for NPC due to low specificity for distinguishing NPC from other EBV-related diseases in endemic regions and high false positive rate for primary screening [33–35].